• Users Online: 400
  • Print this page
  • Email this page


 
 
Table of Contents
LETTER TO THE EDITOR
Year : 2021  |  Volume : 4  |  Issue : 4  |  Page : 790-791

Batra et al.'s reply to Ventrapati and Gheware et al.


1 Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
2 Department of Pathology (Molecular Diagnostics), Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India

Date of Submission10-Nov-2021
Date of Decision21-Nov-2021
Date of Acceptance22-Nov-2021
Date of Web Publication29-Dec-2021

Correspondence Address:
Ullas Batra
Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi - 110 085
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/crst.crst_276_21

Get Permissions


How to cite this article:
Batra U, Nathany S, Diwan H. Batra et al.'s reply to Ventrapati and Gheware et al. Cancer Res Stat Treat 2021;4:790-1

How to cite this URL:
Batra U, Nathany S, Diwan H. Batra et al.'s reply to Ventrapati and Gheware et al. Cancer Res Stat Treat [serial online] 2021 [cited 2022 Jan 20];4:790-1. Available from: https://www.crstonline.com/text.asp?2021/4/4/790/334214



We thank Ventrapati[1] and Gheware et al.[2] for their critical appraisal and comments on our article, “Biomarker Series: KRAS—A narrative review.”[3] The Kirsten rat sarcoma virus (KRAS) oncogene has been widely studied and considered to be implicated in colorectal, lung, and pancreatic cancers. G12C (glycine to cysteine substitution at codon 12 of KRAS) is the most common KRAS point mutation observed in non-small-cell lung carcinoma (NSCLC).[4],[5] KRAS due to its physical structure and close affinity to guanosine-5'-triphosphate (GTP) in its active state was quite unfeasible to target.[6] Nevertheless, the development of sotorasib is indeed a sliver of hope.

We agree with Ventrapati[1] that sotarasib was given accelerated approval by the Food and Drug Administration as it was well tolerated and effective in patients with treatment-refractory NSCLC. However, we still have limited data for the same, and hence, further clinical trials will help unravel the path to targeted therapy for other KRAS-driven tumors like colorectal and pancreatic cancers. The effectiveness of sotorasib has been impressive in the CodeBreaK100 trial[7] among patients with NSCLC. The tumor response however was not as good in colorectal and pancreatic cancers, which can be attributed to the different primary driver mutations. Hence, more studies need to be conducted to explain the difference in tumor responses to sotarasib in NSCLC and other tumors with KRAS mutations.

We are in consensus with Ventrapati[1] in his concern regarding the reach and cost of the drug in a developing country like India, and we agree that united efforts by the government will be required to make this targetable drug available to a large set of patients.

We acquiesce in Gheware et al.'s[2] observation that due to various intrinsic and adaptive resistance mechanisms to KRAS G12C inhibition, an in-depth search of a combination of drugs should be executed to achieve better outcomes and survival rates in patients harboring KRAS mutations. KRAS-mutant NSCLCs are further categorized molecularly on the basis of proteomic data into three subtypes: KRAS with concomitant TP53 mutations, KRAS with inactivating mutation in the liver kinase b1, and KRAS with deletions of CDKN2A and CDKN2B.[8] These molecularly defined subgroups have distinctive responses to chemotherapy and immunotherapy. Nevertheless, we need to delve into more clinical trials possibly with combinations of drugs in these molecular subgroups to untangle the knots for better comprehension, as this could likely pave the path for better tailored therapies in future.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
  References Top

1.
Ventrapati P. Old targets, new bullets, nursing fresh hope. Cancer Res Stat Treat 2021;4:788-9.  Back to cited text no. 1
  [Full text]  
2.
Gheware A, Rathor A, Jain D. From bench to bedside and beyond: Challenges in direct KRAS targeting. Cancer Res Stat Treat 2021;4:789-90.  Back to cited text no. 2
  [Full text]  
3.
Batra U, Nathany S. Biomarker series: KRAS – A narrative review. Cancer Res Stat Treat 2021;4:516-23.  Back to cited text no. 3
  [Full text]  
4.
Uras IZ, Moll HP, Casanova E. Targeting KRAS mutant non-small-cell lung cancer: Past, present and future. Int J Mol Sci 2020;21:4325.  Back to cited text no. 4
    
5.
Chatterjee K, Mukherjee P, Hoque J, Das M, Saha S. Extended RAS mutations (KRAS and NRAS) in patients with colorectal cancers in eastern India: An observational study. Cancer Res Stat Treat 2021;4:244-50.  Back to cited text no. 5
  [Full text]  
6.
Agarwal A, Pragya R, Khaddar S, Kapoor A. Sotorasib – An inhibitor of KRAS p.G12c mutation in advanced non-small cell carcinoma: A narrative drug review. Cancer Res Stat Treat 2021;4:524-8.  Back to cited text no. 6
    
7.
Hong DS, Fakih MG, Strickler JH, Desai J, Durm GA, Shapiro GI, et al. KRASG12C inhibition with sotorasib in advanced solid tumors. N Engl J Med 2020;383:1207-17.  Back to cited text no. 7
    
8.
Hong DS, Kuo J, Sacher AG, Barlesi F, Besse B, Kuboki Y, et al. CodeBreak 100: Phase I study of AMG 510, a novel KRASG12C inhibitor, in patients (pts) with advanced solid tumors other than non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). J Clin Oncol 2020;38:3511.  Back to cited text no. 8
    




 

Top
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
References

 Article Access Statistics
    Viewed120    
    Printed12    
    Emailed0    
    PDF Downloaded9    
    Comments [Add]    

Recommend this journal